FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Molecular Determinantion of Outcomes in a Study with Pembrolizumab for Advanced... August 25, 2021 Educators Raise Money in Memory of Teacher Who Dedicated Herself to... January 19, 2021 Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 Insights Into the Biology of Response and Resistance to MAPK Pathway... October 16, 2024 Load more HOT NEWS Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab Improving Care for Underserved People With Cancer and Evaluating Delays in... ΣΤΑΤΙΣΤΙΚΑ Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk...
